Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses.
Coronavirus
Infectious disease
Serology
Journal
Journal of clinical immunology
ISSN: 1573-2592
Titre abrégé: J Clin Immunol
Pays: Netherlands
ID NLM: 8102137
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
13
07
2020
accepted:
15
02
2021
pubmed:
17
3
2021
medline:
22
7
2021
entrez:
16
3
2021
Statut:
ppublish
Résumé
In order to properly understand the spread of SARS-CoV-2 infection and development of humoral immunity, researchers have evaluated the presence of serum antibodies of people worldwide experiencing the pandemic. These studies rely on the use of recombinant proteins from the viral genome in order to identify serum antibodies that recognize SARS-CoV-2 epitopes. Here, we discuss the cross-reactivity potential of SARS-CoV-2 antibodies with the full spike proteins of four other betacoronaviruses that cause disease in humans, MERS-CoV, SARS-CoV, HCoV-OC43, and HCoV-HKU1. Using enzyme-linked immunosorbent assays (ELISAs), we detected the potential cross-reactivity of antibodies against SARS-CoV-2 towards the four other coronaviruses, with the strongest cross-recognition between SARS-CoV-2 and SARS /MERS-CoV antibodies, as expected based on sequence homology of their respective spike proteins. Further analysis of cross-reactivity could provide informative data that could lead to intelligently designed pan-coronavirus therapeutics or vaccines.
Identifiants
pubmed: 33725211
doi: 10.1007/s10875-021-00997-6
pii: 10.1007/s10875-021-00997-6
pmc: PMC7962425
doi:
Substances chimiques
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
906-913Subventions
Organisme : NIBIB NIH HHS
ID : Intramural Research Program
Pays : United States
Organisme : National Institute of Allergy and Infectious Diseases
ID : Intramural Research Program
Organisme : NCATS NIH HHS
ID : Intramural Research Program
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261200800001C
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261200800001E
Pays : United States
Commentaires et corrections
Type : UpdateOf
Références
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Nat Commun. 2020 May 4;11(1):2251
pubmed: 32366817
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Science. 2020 May 8;368(6491):630-633
pubmed: 32245784
Nat Commun. 2021 Jan 4;12(1):113
pubmed: 33397956
Sci Adv. 2019 Apr 10;5(4):eaav4580
pubmed: 30989115
Clin Vaccine Immunol. 2010 Dec;17(12):1875-80
pubmed: 20943876
Sci Transl Med. 2021 Jul 7;13(601):
pubmed: 34158410
Lancet. 2020 Apr 4;395(10230):1101-1102
pubmed: 32247384
J Clin Virol. 2012 Feb;53(2):135-9
pubmed: 22188723
J Infect Dis. 2021 Mar 3;223(5):802-804
pubmed: 33257936
Can J Infect Dis Med Microbiol. 2006 Nov;17(6):330-6
pubmed: 18382647
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Annu Rev Virol. 2016 Sep 29;3(1):237-261
pubmed: 27578435
Nat Rev Microbiol. 2009 Mar;7(3):226-36
pubmed: 19198616
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Adv Virus Res. 2018;100:163-188
pubmed: 29551135
J Clin Microbiol. 2010 Aug;48(8):2940-7
pubmed: 20554810
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
Protein Expr Purif. 2020 Oct;174:105686
pubmed: 32504802
J Virol. 2003 Aug;77(16):8801-11
pubmed: 12885899